Dermatology

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

LEADderm 2026 brings dermatology leaders to Newport Beach, California, August 29-30, for sessions on leadership, AI in education, and career growth.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and building patient trust and adherence.

In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.

Dallas allergist-immunologists discuss real-world use of non-steroidal topicals in AD, steroid phobia, and the nematode story.

In this interview, Robert Sarkany, MD, FRCP, explains the biology behind erythropoietic protoporphyria and how PORT-77 targets its underlying cause.

Tiffany Mayo, MD, reflects on the pressure of visibility in medical leadership and why boundary-setting becomes essential.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and improves care for skin of color.

Raj Chovatiya, MD, PhD, discusses why 2-year BE HEARD EXT data support earlier systemic therapy discussions and where unmet needs remain for HS.

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

Raj Chovatiya, MD, PhD, discusses why bimekizumab response durability in HS held steady regardless of disease duration, and what it means for care.

Pooled 2-year data show bimekizumab drove greater high-threshold HS responses in patients with shorter versus longer disease duration.

Tiffany Mayo, MD, discusses the pressure of representation in medical leadership, setting boundaries, and staying authentic as a woman of color.

Recent phase 2a findings on PORT-77 show rapid, dose-dependent plasma PPIX reductions in erythropoietic protoporphyria and X-linked protoporphyria.

Sonelokimab hit its primary ACR50 end point and all key secondary end points in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Roxana Daneshjou, MD, PhD, outlines steps to close AI equity gaps in dermatology, from diverse data sets to camera testing for skin of color.

In the phase 3 VALOR trial, oral brepocitinib 30 mg significantly improved myositis and skin disease activity versus placebo in treatment-refractory dermatomyositis.

A Stanford dermatologist explains how AI systems can reinforce racial bias in health care and underperform on skin cancer detection in darker skin.

Meagen McCusker, MD, discusses trusting instinct over rigid planning and why female physicians should lean on each other during career transitions.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

Meagen McCusker, MD, shares why academic medicine's rigid schedule pushed her toward private practice and building an empowering, autonomy-focused culture.

New STOP-HS trial data show durable povorcitinib response through week 54, with a favorable safety profile in hidradenitis suppurativa.